The American Society for Bone and Mineral Research developed 13 clinical recommendations (7 primary and 6 secondary) to address the undertreatment of osteoporosis-related fractures and prevent secondary fracture among persons aged ≥65 years with hip or vertebral fractures.
A meta-analysis found that teriparatide and denosumab may be the most efficacious therapy for prevention of glucocorticoid-induced vertebral fractures.
Simple Fibromyalgia Assessment Screening Tool indices may facilitate the diagnosis of fibromyalgia in the routine care of patients with other rheumatic diseases.
Patients with greater BMD improvement after 1 year of denosumab are more likely to lose BMD after the transition to alendronate therapy in the second year.
Burosmab may restore phosphorus homeostasis and improve mineralization defect in in patients with X-linked hypophosphatemia.
Nitrogen bisphosphonate use in women may be associated with both better survival and a significant reduction in the rate of bone loss.
NKTR-181 was found to be a safe, effective, and well tolerated treatment over the long term in patients with moderate to severe chronic low back pain.
Aquatic physiotherapy may not be superior to a health education program in treating women with fibromyalgia.
More than a quarter of postmenopausal women and men ≥50 years of age were found to have osteoporosis a decade after undergoing Roux-en-Y gastric bypass surgery.
The prevalence of neuropathic-like pain was found to be high in patients with psoriatic arthritis, a condition that may be associated with higher disease activity and fibromyalgia.
